Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 13, 2020 08:30 ET | Source: Emerald Bioscience, Inc.

Emerald Bioscience Provides Update on Recent Progress and Expected 2020 Milestones

Company prepares to enter the clinic in 2020 to test NB1111 (THCVHS) in glaucoma Preclinical formulation testing proprietary analog of CBD examining the utility of CBDVHS in the eye, brain, and...
March 18, 2019 07:30 ET | Source: Nemus Bioscience, Inc.

Nemus Bioscience Reports Nanoemulsion of NB1111 Superior to First-Line Therapy, Latanoprost, in Lowering Intraocular Pressure in Validated Normotensive Animal Model Testing

Prodrug of THC Outperformed Latanoprost at Multiple Timepoints in Multiple Dosing Study NB1111 Formulation Extends Pharmaceutical Activity Time to Support Once-Daily to Twice-Daily Topical Dosing ...
October 15, 2018 08:30 ET | Source: Nemus Bioscience, Inc.

Nemus Bioscience to Present at BIO Investor Forum

LONG BEACH, CA, Oct. 15, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nemus Bioscience, Inc. (OTCQB: NMUS), focused on the development of cannabinoid-based therapeutics to address global medical...
October 08, 2018 08:00 ET | Source: Nemus Bioscience, Inc.

Nemus Bioscience Announces that Emerald Health Sciences has Provided a Credit Facility of up to $20 Million and Adopted an Open Market Share Purchase Program of up to 10 Million Common Shares

Avtar Dhillon, MD, appointed as Executive Chairman of Nemus LONG BEACH, CA, Oct. 08, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nemus Bioscience, Inc. (OTCQB: NMUS), focused on the...
March 07, 2018 08:30 ET | Source: Nemus Bioscience, Inc.

NEMUS Bioscience to Participate in Sachs BioCapital USA Forum at the New York Academy of Sciences

COSTA MESA, CA., March 07, 2018 (GLOBE NEWSWIRE) -- NEMUS Bioscience, Inc. (OTCQB: NMUS), focused on the development of cannabinoid-based therapeutics to address global medical indications,...